Retina/Vitreous News

The K8 implant, a first-in-class dual inflammasome inhibitor, demonstrated positive efficacy and safety at 3 months in five patients with bilateral geographic atrophy, according to a press release from Inflammasome Therapeutics.

Linsitinib, an oral small molecule under development for the treatment of thyroid eye disease, demonstrated proptosis reduction and safety in the phase 2b/3 LIDS trial, according to a press release from Sling Therapeutics.

CHICAGO — In this video, Clement K. Chan, MD, FACS, discusses highlights from the AAO meeting, including presentations on pegcetacoplan and avacincaptad pegol for the treatment of geographic atrophy.

The foveal avascular zone, or FAZ, area deteriorated at 12 months in eyes with stable laser-treated proliferative diabetic retinopathy and macular capillary nonperfusion, but vision loss was not common, according to a study.

CHICAGO — In this video, Clement K. Chan, MD, FACS, discusses a presentation from the AAO meeting on multimodal imaging to assess geographic atrophy.

CHICAGO — In this video from the AAO meeting, Joan W. Miller, MD, chair of ophthalmology at Mass Eye and Ear, discusses the role of AREDS vitamins in slowing the progression of geographic atrophy.

RhyGaze secured $86 million in a Series A financing round, which will be used to further the development of the company’s lead candidate gene therapy for optogenetic vision restoration, according to a press release.

4D Molecular Therapeutics reported positive interim data from the first part of the SPECTRA clinical trial investigating 4D-150 in patients with diabetic macular edema, according to a press release.

City Therapeutics and Bausch + Lomb have entered into a strategic collaboration focused on the development of an RNA interference-based treatment for geographic atrophy, according to a press release.